Modality
Vaccine
MOA
SGLT2i
Target
TNFα
Pathway
Wnt
CSUMSRA
Development Pipeline
Preclinical
Aug 2018
→ Apr 2029
PreclinicalCurrent
NCT03288489
1,267 pts·CSU
2018-11→TBD·Terminated
NCT04296448
1,183 pts·MS
2018-08→2029-04·Recruiting
2,450 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-04-203.1y awayInterim· MS
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
Preclinical
Recruit…
Preclinical
Termina…
Catalysts
Interim
2029-04-20 · 3.1y away
MS
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03288489 | Preclinical | CSU | Terminated | 1267 | Biomarker |
| NCT04296448 | Preclinical | MS | Recruiting | 1183 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| Motazanubrutinib | Biogen | Preclinical | CD38 | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| 369-4107 | Hansoh Pharma | Phase 2 | TNFα | |
| VKT-4052 | Viking Therapeutics | Phase 2/3 | TNFα |